LY 3451838
Alternative Names: LY-3451838; PACAP 38 antibody - Eli Lilly and CompanyLatest Information Update: 28 Nov 2023
At a glance
- Originator Eli Lilly and Company
- Class Antimigraines; Monoclonal antibodies
- Mechanism of Action Pituitary adenylate cyclase-activating polypeptide receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Migraine
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in Migraine(In volunteers) in Denmark (Infusion)
- 09 Nov 2022 Eli Lilly and Company completes a phase II trial in Migraine (Treatment-resistant) in USA (NCT04498910)
- 28 Jan 2022 No recent reports of development identified for phase-I development in Migraine(In volunteers) in Singapore (IV)